E10030 sham intravitreal injection

DRUG2 trials

Sponsors

Ophthotech Corporation

Conditions

Age-Related Macular Degeneration

Phase 3

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

TerminatedNCT01940900

Ophthotech CorporationAge-Related Macular Degeneration

Start: 2013-08-31End: 2016-12-31Updated: 2024-10-30

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

TerminatedNCT01944839

Ophthotech CorporationAge-Related Macular Degeneration

Start: 2013-08-31End: 2016-12-31Updated: 2024-10-30